Quick Answer
Serina Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $130.0 thousand for the year ending 2025.
- Serina Therapeutics, Inc. showed an increase of +132.1% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Serina Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Serina Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 90.7%.
- Historical annual values: Fiscal year 2025: $130.0 thousand | Fiscal year 2024: $56.0 thousand | Fiscal year 2023: $3.15 million | Fiscal year 2022: $34.0 thousand | Fiscal year 2021: $144.0 thousand | Fiscal year 2020: $361.0 thousand | Fiscal year 2019: $1.73 million | Fiscal year 2018: $1.40 million | Fiscal year 2017: $1.40 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: